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translations. RESULTS: Challenges emerged at two levels. a) At the conceptual level, it 
proved challenging for a linguist to differentiate the distinct but related psychiatric
states investigated by the 16 domains present in the questionnaire. b) At the translation
level, the formulation had to meet the following requirements: i) accurately convey the
concepts and ii) be understandable by the layman. These requirements were all the more
crucial in the context of face-to-face diagnostic interviews where mutual and consistent 
comprehension of terms is essential and may inﬂ uence the overall results. CONCLU-
SIONS: The M.I.N.I. translations were produced to ensure concordance with existing
translations, conceptual equivalence across and linguistic consistency within languages 
to facilitate comparison and pooling of data. This was made possible through the close 
collaboration between linguists and psychiatrists, under the guidance of a coordinating 
centre. The results of the project suggest promoting similar collaboration when trans-
lating other mental health measures in the future.
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OBJECTIVES: The Subjective Well-being Under Neuroleptic – Short version (SWN-S)
has been translated into 30 different languages and is currently being translated into 
further languages. The SWN-S is designed to assess the subjective efﬁ cacy of neuro-
leptic medication. The objective of this study was to produce translations that are 
conceptually equivalent to the original and to other language versions, ensuring the 
relevance of the translations within the target cultures. METHODS: A standard
methodology was employed: two forward translations, a reconciliation of the forward
translations, two back translations, back translation review; or an in-country review;
linguistic validation interviews with ﬁ ve stable patients with schizophrenia in each 
country and two proofreadings. RESULTS: Numerous cultural and linguistic issues
became apparent throughout the translation process, as follows: – The concepts
behind some of the English items were unclear to linguists not specialising in schizo-
phrenia. However, pilot testing revealed that amongst the target population, the
wording was correctly understood. – “I ﬁ nd it easy to draw a line between myself and 
others” was difﬁ cult to translate due to numerous possible connotations of this state-
ment. After consultation with the developer, an accurate connotation was able to be 
conveyed to translators. – “Not in control of myself” did not mean “no self control,” 
contrary to how it had been understood in certain language versions. This was clariﬁ ed 
by the developer. – The item ‘my body feels familiar’ was problematic in some lan-
guages; it was impossible to translate literally in Lithuanian due to linguistic con-
straints, and also problematic in Malay. The closest available wording was determined
and discussed with patients. CONCLUSIONS: The SWN-S has been translated and 
linguistically validated in 30 languages using a rigorous translation process. A number
of cultural and linguistic issues became apparent and were resolved. The measure is
now appropriate for use in multinational trials.
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OBJECTIVES: Different generic preference-based health-related quality of life 
(HRQOL) measures may not yield similar quality-adjusted life expectancy, challenging
the meaning of incremental cost-effectiveness ratios in league tables. This study com-
pares corresponding domain scores from different HRQOL measures to evaluate the 
extent to which they tap into the same or unique constructs. METHODS: The SF-36 
(v2), EQ-5D, and HUI-3 were administered to 3844 U.S. adults in the National Health 
Measurement Study, a cross-sectional random-digit dial telephone survey. Mean 
domain and preference-based scores were calculated. Convergent and discriminant 
validity were evaluated by multi-trait multi-method (MTMM) analysis of the three 
HRQOL instruments across the attributes of physical functioning (SF-36 physical 
functioning, HUI-3 ambulation, and EQ-5D mobility), mental health (SF-36 mental 
health, HUI-3 emotion, and EQ-5D anxiety/depression), and pain (SF-36 bodily pain, 
HUI-3 pain, and EQ-5D pain/discomfort). RESULTS: Mean scale scores of the SF-36,
HUI-3, and EQ-5D, respectively, ranged from 47.2 (/10.7) to 53.4 (/10.2) [46.9 
(/11.0) and 53.0 (/10.1) for PCS and MCS], 0.928 (/0.121) to 0.996 (/0.028), 
and 1.0171 (/0.269) to 1.596 (/0.587). Mean preference-based scores obtained
from the SF-36 (calculated from the SF-6D), HUI-3, and EQ-5D were 0.765 (/0.144), 
0.766 (/0.275), and 0.838 (/0.173), respectively (p  0.001 for Bonferroni-
corrected paired t-tests comparing EQ-5D to both SF-36 and HUI-3). The MTMM
matrix had average validity and off-diagonal correlations of 0.622 and 0.404, indicat-
ing high convergent validity. MTMM analysis also showed 91% of convergent validity 
correlations to be signiﬁ cantly larger (p  0.05) than relevant other correlations in the 
MTMM matrix, providing substantial support for discriminant validity. CONCLU-
SIONS: Although the mean preference-based score obtained from the EQ-5D was
different from the SF-36 and HUI-3, MTMM analysis demonstrated good support for 
construct validity among analogous domains of these measures. Further analysis is
required to better understand how similar elements of different generic HRQOL
instruments impact preference-based scores.
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This paper applies commonsense principles to determine the basis for selecting any 
valuation method. At its centre is the concept that health states compete for location 
within a restricted value space in which full health is assigned the value 1 and dead
the value 0. A descriptive health classiﬁ cation system may generate a large of states 
(972,000 / 18,000 and 245 for HUI3, SF6D and EQ-5D respectively). This argues for
a valuation method that can discriminate between states separated by very small value 
differences. Were all states to have a unique value these differences would be incredibly 
small (1.03E-6, 5.5E-5 & 0.004 respectively). TTO and SG methods used to calibrate
these systems fail a basic credibility test. The numeric output implies a degree of 
measurement performance unlike any other area of human judgement – even those 
with more concrete implications (such as controlling the warmth of our environment)
which are better understood but that report far cruder measurement properties. A 
just-noticeable difference (JND) of 2 degrees Centigrade is reported when testing 
human subjects’ response to temperature. If we assume that human judgement “accu-
rately” discriminates between health states separated by (say) 5 points on a 0–100
VAS scale then we should expect a limited number (n  21) of unique value points. 
Methods that purport to represent health state values with more than this level of 
accuracy imply a human judgement capacity that lacks supportive evidence. A basic
test for any method is whether or not there is evidence that individuals CAN in fact 
discriminate between adjacent health states separated by such small value distances.
Procedures which make minimal assumptions about human judgement are to be pre-
ferred to those with untested performance characteristics. Spurious “accuracy” in 
reported values for health states can be avoided by limiting decrements to a maximum 
of 2 decimal places.
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OBJECTIVES: Apply and further validate the Patient Satisfaction with Pharmaceutical
Care Questionnaire (PSPCQ) in a different pharmacy practice setting. METHODS:
Five hundred questionnaires were distributed to patients dropping off a prescription
at a high-volume (500 prescriptions/day), 24-hour chain pharmacy, during a 2-week 
period. PSPCQ is a self-administered questionnaire and comprises of 20 Likert-type 
items that measure patient satisfaction with functional and technical dimensions of 
pharmacy services, which are represented by Friendly Explanation (FE) and managing
therapy” (MT) subscales. Patient satisfaction and psychometric properties of 
PSPCQ were evaluated using SPSS. Pearson’s correlation and Student’s t-test were 
used. RESULTS: Survey response rate was 24.2% (n  121). Chronbach’s alpha 
for FE and MT scales were 0.979 and 0.980, respectively. Mean scale scores for 
Global, FE, and MT were 2.88 (SD  1.28), 2.98 (SD  1.27), and 2.74 (SD  1.35), 
respectively. Mean differences in mean scores were 0.24 (P  0.001) between FE and 
MT scales, 0.097 (P  0.001) between Global and FE scales, and 0.15 (P  0.001) 
between Global and MT scales. Inter-scale correlation coefﬁ cients were 0.938
(P  0.001) for FE and MT, 0.988 (P  0.001) for Global and FE, and 0.979
(P  0.001) for Global and MT. “How well the pharmacist answers your questions” 
received second highest rating of 3.21, while “Promptness of prescription drug 
service” received the lowest rating of 2.58, out of the twenty items. CONCLUSIONS:
Signiﬁ cantly higher (P  0.001) overall mean score on MT scale compared to FE scale 
suggests that patients distinguish between activities related to pharmaceutical care 
(MT) and friendly service (FE); and, since usually higher scores are expected from
patients on familiar items, construct validity was demonstrated. Practicing pharma-
cists, in this setting, supported face validity. PSPCQ demonstrated external validity, in 
a high-volume retail pharmacy setting. PSPCQ can be used to assess patient-reported 
quality, in addition to patient awareness, of pharmaceutical care in the community 
pharmacy setting.
PMC72
ASSESSING ANXIETY AND DEPRESSION ON AN INTERNATIONAL
LEVEL
Neewoor S1, D’uva F1, Le Halpère A2, Kroenke K3, Engels DJ4
1Mapi Research Institute, LYON, France, 2Sanoﬁ -Aventis, Antony, France, 3Regenstrief Institute
for Health Care, Indianapolis, IN, USA, 4Pﬁ zer, New York, NY, USA
OBJECTIVES: Prior to use in an international study, the Generalized Anxiety Disorder 
Screener (GAD-7) and the Patient Health Questionnaire 9 (PHQ-9) underwent lin-
guistic validation into 67 and 24 languages respectively. A rigorous methodology was
required to ensure conceptual equivalence and cultural relevance between the different 
languages and the original US English instruments. METHODS: The translation
process was conducted by a specialist in each target country, in collaboration with the
developer, using the following standardized methodology: (1) two forward translations 
by professional translators (native speakers of the target language); (2) analysis of the 
translations by the specialist; (3) backward translation by a native English speaker; 
(4) comparison of source and backward version and (5) comprehension test on a
sample of healthy subjects in each target country. Existing translations were integrated
